Contacts:
Accuri Cytometers
Media
Jennifer A. Baird
GendeLLindheim BioCom Partners
Chief Executive Officer
Jennifer Anderson
(734) 994-8000
(212) 918-4642
ACCURI CYTOMETERS COMPLETES $4 MILLION SERIES D FINANCING
--Funds Will Provide Additional Working Capital to Support Strong Market Demand
for Accuri C6 Flow Cytometer® System and Accuri CSampler™--
ANN ARBOR, MI, July 13, 2009 – Accuri Cytometers, Inc. today announced the completion of a $4
million Series D financing. The financing included current investors Fidelity Biosciences, Flagship
Ventures, Baird Venture Partners and Arboretum Ventures, as well as the InvestMichigan! Program co-
managed by Credit Suisse. Accuri will use the proceeds from the Series D financing to provide additional
working and growth capital to support the rapid market acceptance of the Accuri C6 Flow Cytometer®
System, a revolutionary product designed to bring the power of flow cytometry analysis to the laboratory
of every life science researcher, and the recently introduced Accuri CSampler™, an optional accessory
that adds user-friendly automation to the C6 system.
“With our first two products experiencing rapid market acceptance and our European operations newly
underway, we have secured additional capital to build out our manufacturing and customer support
capabilities in Michigan and to continue to expand our commercial presence globally,” said Jennifer Baird,
CEO of Accuri. “In these challenging times, we are gratified that all of our existing investors chose to
participate in the Series D financing at a higher valuation. We are especially pleased that the
InvestMichigan! Program, co-managed by Credit Suisse and championed by Governor Jennifer
Granholm, became a significant new investor.”
Explicitly designed for routine use by biomedical resea